PMVP - PMV Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cranbury,
United States
Type: Equity
PMVP price evolution
PMVP
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.35 | $48.48 | $38.53 | $52.88 |
| Short term investments | $164.39 | $150.28 | $165.35 | $149.86 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $218.79 | $202.46 | $207.41 | $205.3 |
| Long term investments | $15.12 | $25.5 | $36.18 | |
| Property, plant & equipment | $18.57 | $19.11 | $19.05 | $19.37 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $18.75 | $34.42 | $44.74 | $55.73 |
| Total investments | $164.39 | $165.41 | $190.86 | $186.04 |
| Total assets | $237.54 | $236.88 | $252.15 | $261.03 |
| Current liabilities | ||||
| Accounts payable | $4.53 | $0.86 | $3.24 | $1.68 |
| Deferred revenue | ||||
| Short long term debt | $1.15 | $0.88 | $0.85 | |
| Total current liabilities | $11.38 | $12.06 | $14.03 | $10.72 |
| Long term debt | $11.84 | $12.14 | $12.43 | $12.7 |
| Total noncurrent liabilities | $11.84 | $12.14 | $12.43 | $12.7 |
| Total debt | $12.99 | $13.02 | $13.29 | $12.7 |
| Total liabilities | $23.22 | $24.2 | $26.46 | $23.41 |
| Shareholders' equity | ||||
| Retained earnings | -$326.49 | -$325.27 | -$310 | -$294.25 |
| Other shareholder equity | -$0.18 | -$0.13 | $0.22 | -$0.35 |
| Total shareholder equity | $214.31 | $212.68 | $225.69 | $237.61 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $38.53 | $109.12 | $173.29 | $361.42 |
| Short term investments | $165.35 | $132.76 | $124.7 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $207.41 | $247.01 | $301.29 | $364.76 |
| Long term investments | $25.5 | $2.5 | $16.91 | |
| Property, plant & equipment | $19.05 | $20.49 | $13.15 | $0.57 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $44.74 | $23.3 | $30.28 | $0.77 |
| Total investments | $190.86 | $135.25 | $141.61 | |
| Total assets | $252.15 | $270.31 | $331.57 | $365.53 |
| Current liabilities | ||||
| Accounts payable | $3.24 | $3 | $3.19 | $1.61 |
| Deferred revenue | ||||
| Short long term debt | $0.85 | $0.53 | $0.4 | |
| Total current liabilities | $14.03 | $10.83 | $12.22 | $6.41 |
| Long term debt | $12.43 | $13.45 | $10.79 | |
| Total noncurrent liabilities | $12.43 | $13.45 | $10.79 | |
| Total debt | $13.29 | $13.98 | $11.19 | |
| Total liabilities | $26.46 | $24.28 | $23.01 | $6.41 |
| Shareholders' equity | ||||
| Retained earnings | -$310 | -$241.04 | -$167.73 | -$109.88 |
| Other shareholder equity | $0.22 | -$0 | -$0.08 | |
| Total shareholder equity | $225.69 | $246.03 | $308.56 | $359.12 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $14.63 | $13.19 | $13.38 | $13.59 |
| Selling, general & administrative | $5.54 | $5.04 | $5.52 | $6.04 |
| Total operating expenses | $20.17 | $18.22 | $18.9 | $19.63 |
| Operating income | -$20.17 | -$18.22 | -$18.9 | -$19.63 |
| Income from continuing operations | ||||
| EBIT | -$17.39 | -$15.27 | -$15.76 | -$16.64 |
| Income tax expense | -$16.17 | -$0 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$1.21 | -$15.27 | -$15.76 | -$16.64 |
| Income (for common shares) | -$1.21 | -$15.27 | -$15.76 | -$16.64 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $55.88 | $51.99 | $36.49 | $23.93 |
| Selling, general & administrative | $24.25 | $25.05 | $21.8 | $11.01 |
| Total operating expenses | $80.13 | $77.04 | $58.29 | $34.94 |
| Operating income | -$80.13 | -$77.04 | -$58.29 | -$34.94 |
| Income from continuing operations | ||||
| EBIT | -$68.96 | -$73.33 | -$57.82 | -$34.43 |
| Income tax expense | $0 | -$0.01 | $0.02 | $0.01 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$68.96 | -$73.32 | -$57.85 | -$34.44 |
| Income (for common shares) | -$68.96 | -$73.32 | -$57.85 | -$34.44 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$1.21 | -$15.27 | -$15.76 | -$16.64 |
| Operating activities | ||||
| Depreciation | $0.37 | $0.36 | -$0.01 | $0.36 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.77 | $2.61 | $2.97 | $3.32 |
| Total cash flows from operations | -$1.6 | -$16.18 | -$12.09 | -$15.66 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.59 | -$0.2 | -$0.04 |
| Investments | $2.33 | $26.76 | -$2.39 | -$33.59 |
| Total cash flows from investing | $2.32 | $26.17 | -$2.59 | -$33.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.14 | $0.29 | $33.15 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.14 | $0.29 | $33.15 | |
| Effect of exchange rate | $0.01 | -$0.03 | $0.03 | |
| Change in cash and equivalents | $0.87 | $9.95 | -$14.35 | -$16.15 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$68.96 | -$73.32 | -$57.85 | -$34.44 |
| Operating activities | ||||
| Depreciation | $0.89 | $0.65 | $1.28 | $0.32 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.38 | $10.2 | $5.34 | $1.93 |
| Total cash flows from operations | -$55.66 | -$63.76 | -$46.57 | -$32.74 |
| Investing activities | ||||
| Capital expenditures | -$0.96 | -$7.98 | -$1.35 | -$0.15 |
| Investments | -$49.58 | $6.62 | -$142.24 | $28.06 |
| Total cash flows from investing | -$50.55 | -$1.37 | -$143.58 | $27.91 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $35.58 | $0.96 | $2.02 | $223.18 |
| Net borrowings | ||||
| Total cash flows from financing | $35.58 | $0.96 | $2.02 | $292.97 |
| Effect of exchange rate | $0.03 | |||
| Change in cash and equivalents | -$70.59 | -$64.17 | -$188.13 | $288.14 |
News
Fundamentals
| Market cap | $82.44M |
|---|---|
| Enterprise value | $46.08M |
| Shares outstanding | 51.52M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$63.97M |
| EBIT | -$65.05M |
| Net Income | -$48.88M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.69 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.72 |
| EV/EBIT | -0.71 |
| P/S ratio | N/A |
| P/B ratio | 0.38 |
| Book/Share | 4.16 |
| Cash/Share | 0.96 |
| EPS | -$0.95 |
|---|---|
| ROA | -19.80% |
| ROE | -21.96% |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | 0.41 |
| Current ratio | 19.22 |
| Quick ratio | 19.22 |